Genome Therapeutics, Astra AB deal

GENE and Astra will collaborate to develop therapeutics, vaccines and diagnostics for peptic ulcers caused by Helicobacter pylori.

Astra will provide up to $22 million for exclusive rights to technologies related to the H. pylori pathogen. License fees and R&D payments make up the $11 million amount that is non-contingent. The remaining $11 million is achievable through milestones. ...